Breaking: Ladenburg Reconfirms $7.5000 Target On ADMA Biologics (NASDAQ:ADMA) Shares, Reconfirms Their Original Buy Rating

June 13, 2018 - By Richard Conner

ADMA Biologics, Inc. (NASDAQ:ADMA) Logo

Investors sentiment decreased to 2.86 in 2018 Q1. Its down 0.14, from 3 in 2017Q4. It worsened, as 1 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 11 funds opened positions while 9 raised stakes. 15.52 million shares or 0.06% less from 15.53 million shares in 2017Q4 were reported.

Broadfin Capital Limited Co owns 720,529 shares for 0.52% of their portfolio. Morgan Stanley holds 0% or 13,011 shares. Goldman Sachs Gp reported 93,294 shares stake. Susquehanna Intll Group Ltd Liability Partnership owns 94,476 shares for 0% of their portfolio. Iguana Health Lc accumulated 600,000 shares. Vanguard Group invested in 0% or 886,987 shares. Perceptive Advsr Ltd holds 0.49% in ADMA Biologics, Inc. (NASDAQ:ADMA) or 3.82 million shares. Natl Bank Of New York Mellon Corporation has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Advisory Svcs Network Ltd Liability Corporation owns 0% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 1,700 shares. Element Capital Mngmt Limited Liability Co invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). Highbridge Capital Management Lc invested 0.02% in ADMA Biologics, Inc. (NASDAQ:ADMA). Geode Cap Limited Liability Company stated it has 112,000 shares. Spark Inv Mngmt Lc reported 22,200 shares. 18,730 were reported by Sigma Planning Corporation. Jefferies Group Inc Limited Liability Com has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA).

Since June 8, 2018, it had 5 buys, and 0 insider sales for $744,504 activity. 52,302 ADMA Biologics, Inc. (NASDAQ:ADMA) shares with value of $250,004 were bought by Grossman Jerrold B. $24,999 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) shares were bought by RICHMAN ERIC I. Grossman Adam S had bought 73,222 shares worth $350,001 on Friday, June 8. LENZ BRIAN had bought 5,000 shares worth $23,900.

ADMA Biologics (NASDAQ:ADMA) Rating Reaffirmed

Recently, In an analyst note made public on Wednesday, 13 June, ADMA Biologics (NASDAQ:ADMA) shares have had their Buy Rating kept by stock research analysts at Ladenburg, who currently has a $7.5000 price target on company. This target by Ladenburg would indicate the possibile upside of 56.58 % from the last close price.

The stock decreased 1.24% or $0.06 during the last trading session, reaching $4.79. About 261,424 shares traded or 54.89% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 49.86% since June 14, 2017 and is uptrending. It has outperformed by 37.29% the S&P500.

Analysts await ADMA Biologics, Inc. (NASDAQ:ADMA) to report earnings on August, 10. They expect $-0.35 earnings per share, up 36.36 % or $0.20 from last year’s $-0.55 per share. After $-0.35 actual earnings per share reported by ADMA Biologics, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ADMA Biologics, Inc., a biopharmaceutical company, develops, makes, and markets specialty plasma biologics for the treatment of immune deficiencies and infectious diseases. The company has market cap of $216.00 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: which released: “After-Hours Stock Movers 06/07: (ZUMZ) (DOCU) (SFIX) Higher; (MVIS) (ITI) (ADMA) Lower (more…)” on June 07, 2018, also with their article: “ADMA Biologics Announces Closing of $40M Public Offering” published on June 12, 2018, published: “ADMA Biologics Announces Pricing of Public Offering of Common Stock” on June 08, 2018. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: and their article: “Benzinga’s Daily Biotech Pulse: vTv Swoons On Failed Alzheimer’s Trial, Regenxbio Gets FDA Fast Track For RGX-111” published on June 13, 2018 as well as‘s news article titled: “ADMA Biologics Granted US Patent for Treating Respiratory Infections” with publication date: May 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.